Advertisement

Cancer

  • Vito AnneseEmail author
  • Anita Cserbane
Chapter

Abstract

  • The lifetime risk of cancer is on the rise owing to increasing life expectancy and the increased incidence associated with advanced age.

  • In general, when cancer develops or recurs in IBD patients, this may be related to the chronic intestinal inflammation, have no link with IBD or its treatment, and/or may be potentially influenced by the immunosuppressive drugs.

  • Health-care providers caring for patients with IBD are often faced with the challenges of managing the disease in patients with history of neoplastic disease or those who develop cancer for the first time.

  • Few consensus guidelines and studies are available on the management of IBD patients with history of cancer. Most of the clinical data on the potentially detrimental effects of immunosuppressant therapy derives from observational studies of patients with rheumatologic diseases or solid organ transplants.

  • This chapter will offer (a) an understanding into the background cancer risk in IBD patients and (b) analysis and discussion of the risk of cancer related to IBD therapy and, finally, (c) suggest some clues for a multidisciplinary management.

Keywords

Colorectal cancer Cancer risk Cancer recurrence Management 

References

  1. Ali RAR, Dooley C, Comber H et al (2011) Clinical features, treatment, and survival of patients with colorectal cancer with or without inflammatory bowel disease. Clin Gastroenterol Hepatol 9:584-9.e1–584-9.e2Google Scholar
  2. Annese V, Daperno M, Rutter MD et al (2013) European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis 7(12):982–1018CrossRefGoogle Scholar
  3. Annese V, Beaugerie L, Egan L et al (2015) European evidence-based consensus: inflammatory bowel disease and malignancies. J Crohns Colitis 9(11):945–946CrossRefGoogle Scholar
  4. Ariyaratnam J, Subramanian V (2014) Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: a meta-analysis. Am J Gastroenterol 109:163–169CrossRefGoogle Scholar
  5. Askling J, Brandt L, Lapidus A et al (2005) Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut 54:617–622CrossRefGoogle Scholar
  6. Beaugerie L (2013) Lymphoma: the bete noire of the long-term use of thiopurines in adult and elderly patients with inflammatory bowel disease. Gastroenterology 145:927–923CrossRefGoogle Scholar
  7. Beaugerie L (2014) Management of inflammatory bowel disease patients with a cancer history. Curr Drug Targets 15:1042–1048CrossRefGoogle Scholar
  8. Beaugerie L, Brousse N, Bouvier AM et al (2009) Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 374:1617–1625CrossRefGoogle Scholar
  9. Biancone L, Zuzzi S, Ranieri M et al (2012) Fistulizing pattern in Crohn’s disease and pancolitis in ulcerative colitis are independent risk factors for cancer: a single-center cohort study. J Crohns Colitis 6:578–587CrossRefGoogle Scholar
  10. Branco BC, Sachar DB, Heimann TM et al (2009) Adenocarcinoma following Ileal pouch-anal anastomosis for ulcerative colitis: review of 26 cases. Inflamm Bowel Dis 15:295–299CrossRefGoogle Scholar
  11. Brentnall TA, Haggitt RC, Rabinovitch PS et al (1996) Risk and natural history of colonic neoplasia in patients with primary Sclerosing cholangitis and ulcerative colitis. Gastroenterology 110:331–338CrossRefGoogle Scholar
  12. Cairns SR, Scholefield JH, Steele RJ, Dunlop MG, Thomas HJ, Evans GD, Eaden JA, Rutter MD, Atkin WP, Saunders BP, Lucassen A, Jenkins P, Fairclough PD, Woodhouse CR (2010) Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 59:666–689CrossRefGoogle Scholar
  13. Collins PD, Mpofu C, Watson AJ, Rhodes JM (2006) Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev 2:CD000279Google Scholar
  14. Curtis RF, Freedman DM, Ron E, LAG R, Hacker DG, Edwards BK, Tucker MA, Fraumeni JF Jr (2006) New malignancies among cancer survivors: SEER Cancer registries, 1973–2000. National Cancer Institute, BethesdaGoogle Scholar
  15. Eaden JA, Abrams KR, Mayberry JF (2001) The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48:526–535CrossRefGoogle Scholar
  16. Elwood JM, Jopson J (1997) Melanoma and sun exposure: an overview of published studies. Int J Cancer 73:6CrossRefGoogle Scholar
  17. Ha CY, Katz S (2013) Clinical outcomes and management of inflammatory bowel disease in the older patient. Curr Gastroenterol Rep 15:310CrossRefGoogle Scholar
  18. Herrinton LJ, Liu L, Weng X et al (2011) Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol 106:2146–2153CrossRefGoogle Scholar
  19. Jess T, Gamborg M, Matzen P et al (2005) Increased risk of intestinal cancer in Crohn’s disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol 100:2724–2729CrossRefGoogle Scholar
  20. Jess T, Rungoe C, Peyrin-Biroulet L (2012) Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol 10:639–645CrossRefGoogle Scholar
  21. Kotlyar DS, Osterman MT, Diamond RH et al (2011) A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 9:36–41CrossRefGoogle Scholar
  22. Kotlyar DS, Lewis JD, Beaugerie L et al (2015) Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol 13(5):847–58.e4 quiz e48–50CrossRefGoogle Scholar
  23. Lanoy E, Engels EA (2010) Skin cancers associated with autoimmune conditions among elderly adults. Br J Cancer 103:112–114CrossRefGoogle Scholar
  24. Laukoetter MG, Mennigen R, Hannig CM et al (2011) Intestinal cancer risk in Crohn's disease: a meta-analysis. J Gastrointest Surg 15:576–583CrossRefGoogle Scholar
  25. Lees CW, Critchley J, Chee N et al (2009) Lack of association between cervical dysplasia and IBD: a large case-control study. Inflamm Bowel Dis 15:1621–1629CrossRefGoogle Scholar
  26. Lichtenstein GR, Feagan BG, Cohen RD et al (2014) Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT registry. Am J Gastroenterol 109:212–223CrossRefGoogle Scholar
  27. Long MD, Herfarth HH, Pipkin CA et al (2010) Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 8:268–274CrossRefGoogle Scholar
  28. Long MD, Martin CF, Pipkin CA et al (2012a) Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 143:390–399.e1CrossRefGoogle Scholar
  29. Long MD, Martin CF, Pipkin CA et al (2012b) Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 143:390–399.e1CrossRefGoogle Scholar
  30. Lopez A, Mounier M, Bouvier AM et al (2014) Increased risk of acute myeloid leukemias and myelodysplastic syndromes in patients who received thiopurine treatment for inflammatory bowel disease. Clin Gastroenterol Hepatol 12(8):1324–1329CrossRefGoogle Scholar
  31. Magro F, Gionchetti P, Eliakim R et al (2017) Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis 11(6):649–670CrossRefGoogle Scholar
  32. Nyboe Andersen N, Pasternak B, Basit S et al (2014) Association between tumor necrosis factor-alpha antagonists and risk of cancer in patent with inflammatory bowel disease. JAMA 311:2406–2413CrossRefGoogle Scholar
  33. O'Donovan P, Perrett CM, Zhang X et al (2005) Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 309:1871–1874CrossRefGoogle Scholar
  34. Ording AG, Horvath-Puho E, Erichsen R et al (2013) Five-year mortality in colorectal cancer patients with ulcerative colitis or Crohn's disease: a nationwide population-based cohort study. Inflamm Bowel Dis 19:800–805CrossRefGoogle Scholar
  35. Ortiz A, Grando SA (2012) Smoking and the skin. Int J Dermatol 51:13CrossRefGoogle Scholar
  36. Osterman MT, Sandborn WJ, Colombel JF et al (2014) Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease. Gastroenterology 146:941–949CrossRefGoogle Scholar
  37. Pedersen N, Duricova D, Elkjaer M et al (2010) Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies. Am J Gastroenterol 105:1480–1487CrossRefGoogle Scholar
  38. Penn I (1993) The effect of immunosuppression on pre-existing cancers. Transplantation 55:742–747CrossRefGoogle Scholar
  39. Penn I (1997) Evaluation of transplant candidates with pre-existing malignancies. Ann Transplant 2:14–17PubMedGoogle Scholar
  40. Peyrin-Biroulet L, Khosrotehrani K, Carrat F et al (2011) Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 141:1621–1628.e5CrossRefGoogle Scholar
  41. Provenzale D, Wong JB, Onken JE, Lipscomb J (1998) Performing a cost-effectiveness analysis: surveillance of patients with ulcerative colitis. Am J Gastroenterol 93:872–880CrossRefGoogle Scholar
  42. Ramiro S, Gaujoux-Viala C, Nam JL et al (2014) Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 73:529–535CrossRefGoogle Scholar
  43. Rees CJ, Bevan R, Zimmermann-Fraedrich K et al (2016) Expert opinions and scientific evidence for colonoscopy key performance indicators. Gut 65(12):2045–2060CrossRefGoogle Scholar
  44. Singh H, Nugent Z, Demers AA et al (2011a) Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease. Gastroenterology 141:1612–1620CrossRefGoogle Scholar
  45. Singh H, Nugent Z, Demers AA et al (2011b) Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease. Gastroenterology 141:1612–1620CrossRefGoogle Scholar
  46. Singh S, Nagpal SJ, Murad MH et al (2014) Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 12:210–218CrossRefGoogle Scholar
  47. Stobaugh DJ, Deepak P, Ehrenpreis ED (2013) A predictive model of the risk of developing multiple cancers with tumor necrosis factor alpha inhibitor therapy among patients with inflammatory bowel disease. Gastroenterology 1:S410CrossRefGoogle Scholar
  48. Subramanian V, Mannath J, Ragunath K, Hawkey CJ (2011) Meta-analysis: the diagnostic yield of chromoendoscopy for detecting dysplasia in patients with colonic inflammatory bowel disease. Aliment Pharmacol Ther 33:304–312CrossRefGoogle Scholar
  49. Toruner M, Harewood GC, Loftus EV Jr, Sandborn WJ, Tremaine WJ, Faubion WA, Schroeder KW, Egan LJ (2005) Endoscopic factors in the diagnosis of colorectal dysplasia in chronic inflammatory bowel disease. Inflamm Bowel Dis 11:428–434CrossRefGoogle Scholar
  50. von Roon AC, Reese G, Teare J et al (2007) The risk of cancer in patients with Crohn’s disease. Dis Colon Rectum 50:839–855CrossRefGoogle Scholar
  51. Williams CJ, Peyrin-Biroulet L, Ford AC (2014) Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-alpha therapy in inflammatory bowel disease. Aliment Pharmacol Ther 39:447–458CrossRefGoogle Scholar
  52. Wu L, Li P, Wu J, Cao Y, Gao F (2012) The diagnostic accuracy of chromoendoscopy for dysplasia in ulcerative colitis: meta-analysis of six randomized controlled trials. Color Dis 14:416–420CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of GastroenterologyValiant Clinic – Huston MethodistDubaiUAE

Personalised recommendations